Specifically, developments in the pharmacological class of SGLT2 inhibitors over the last few years have rendered them promising in the treatment of DM [21], in the treatment of HF (with both a reduced [19] and a preserved [22,23] ejection fraction), and in the improvement of CKD outcomes [20,24]. Here, SLC5A2 is linked to diabetes mellitus.